Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04479891
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT04480294
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Registration Number
- NCT04479904
The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT04472819
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04470063
- Locations
- 🇨🇳
Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT04464733
- Locations
- 🇨🇳
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04457180
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT04455581
A Phase I Study of SHR1459 in Healthy Subjects
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04455100
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 151
- Registration Number
- NCT04447118
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇧🇪Antwerp University Hospital (UZA), Edegem, Belgium